Pirfenidone's Potential for Motor Recovery following Spinal Cord Compression Injury

Abstract

Objective: The aim of this research was to access the ability of pirfenidone in improving motor activity of hindlimbs in rats following compression injury to spinal cord. Study Design: Experimental lab-based study. Settings: Institute of Basic Medical Sciences, Khyber Medical University Peshawar, Pakistan. Duration: From March 2020 to April 2023. Methods: Injury induction at the T7 spinal cord level was carried out using a 70gm force aneurysm clip in rats. The rats were divided into three groups: Group A received a daily placebo, Group B received a daily dose of pirfenidone at 200 mg/kg/day, and Group C received a daily dose of pirfenidone at 500 mg/kg/day. Each group was further subdivided into two sub-groups, labeled as Groups 1 and 2, each consisting of 5 rats. The experiment lasted for 14 and 28 days. On the final day, all rats underwent BBB scoring to evaluate the motor activity in their hind limbs. Results: BBB scores showed statistically significant differences both between and within groups. Among the SCI groups, those treated with pirfenidone displayed higher BBB scores compared to those without pirfenidone treatment. Conclusion: Pirfenidone may improve motor function post-spinal cord injury by reducing fibrosis, preventing collagen buildup in the core of glial scars, and reducing reactive astrocytosis in the scar's outer region. This dual action could promote axonal regeneration and enhance synaptic connections, aiding in neurological recovery.